Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07562399 · ClinicalTrials.gov registry record · NA
Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT07562399: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT07562399 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 224 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07562399, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.
Primary Outcome
The proportion of participants adhering to adjuvant endocrine therapy (AET) is based on the Simplified Medication Adherence Questionnaire (SMAQ; Knobel et al. J Acq Immune Deficiency Syndromes 2002). SMAQ is a 6-item assesment tool but only the 4 yes/no questions are used for this endpoint. An affirmative answer to any of the 4 questions defines non-adherent status.
Interventions
- BEHAVIORAL Educational video
- BEHAVIORAL Text reminders
- BEHAVIORAL Symptom monitoring card
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2026-09-20 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What is known before NCT07562399 opens enrollment
NCT07562399 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Educational video is the first listed.
NCT07562399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07562399 about?
NCT07562399 is a clinical study titled "Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda". This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impac...
What is the current status of trial NCT07562399?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 224 participants. The study started on 2026-09-20. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07562399?
The interventions under investigation include: Educational video (BEHAVIORAL), Text reminders (BEHAVIORAL), Symptom monitoring card (BEHAVIORAL).
Who is sponsoring clinical trial NCT07562399?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07562399's enrollment target sits among peer trials
224 478th of 2000 higher than 1,520 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI